Biomarker analysis

When organ injury is clinically determined, the injury is often irreversible. Therefore, it is important to have sensitive and accurate assays for determining organ/tissue injury in an early phase. HaemoScan has developed such assays which can determine the release of specific proteins in blood or urine which serve as an indicator for organ specific injury.

(Academic) clinical studies

Biomarkers are gaining popularity because of their early release and the possibility for non-invasive analysis of human health. Biomarkers are measurable parameters that reflect the state of a biological process. An often-cited definition of a biomarker is: “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention [1].” Biomarkers are used to screen for, diagnose or monitor disease and are also used to assess a therapeutic response [2]. The term biomarker is typically used for molecular biomarkers measured in blood. HaemoScan has experience with university medical centers all over the world and has been involved in multiple studies with diverse topics, such as intensive care medicine, nephrology, thoracic surgery, sports medicine and rehabilitation. Our laboratory is equipped with the latest technologies to perform customized studies with small or large batches of samples. Moreover, we are specialized in developing new methods for measuring biomarkers in small amounts of biological fluids, such as plasma, serum or urine, making fast and non-invasive measurements possible. Please feel free to contact us to see if we can be of assistance to your project.
Biomarkers
Figure 1. Schematic representation of frequently performed biomarkers at HaemoScan.


Our biomarker analysis services include:

  • Advice on which biomarkers to analyse.
  • Assistance with sample collection protocol, including labels, tubes/container, storage, etc.
  • Development and validation of new assays, including variation, stability, linearity, recovery and batch control.
  • Performing the actual analysis.
  • Assistance in writing scientific publications (for instance the materials & methods section).

Who make use of our services:

  • Academic institutions.
  • Other contract research organizations.
  • Small and medium-sized enterprises operating in life sciences and pharma.

References
[1] Biomarkers Definitions Working Group Bethesda. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics. 2001;69(3):89–95.
[2] Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechnology. 2006;24(8):971–83.